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Reply
We thank Dr. Houthuizen and colleagues for their interest in our
study (1), which reported that periprocedural permanent pace-
maker implantation among patients undergoing transcatheter aor-
tic valve implantation (TAVI) does not affect mortality during
follow-up through 1 year. Houthuizen and colleagues are con-
cerned by the lack of a sample size calculation and question the
validity of our findings in view of previous pacemaker studies,
namely, the MOST (Mode Selection Trial) and the DAVID
(Dual Chamber and VVI Implantable Defibrillator) trial (2,3), as
well as their own study suggesting a negative prognostic impact of
new onset left bundle branch block after TAVI (4).
Our study is the first report to address the impact of permanent
acemaker implantation on mortality among patients undergoing
AVI, and we acknowledge that our findings are exploratory and
ot conclusive as it was limited to 2 institutions and high-risk
atients. The number of patients and accumulated events were
mall, and 95% confidence intervals of hazard ratios wide. The
resent study should, therefore, be the impetus to address this issue
n prospectively planned larger cohort studies.
The MOST and the DAVID trials have shown a negative
mpact of right ventricular pacing by increasing heart failure
ospitalization but not mortality. Of note, these findings cannot be
xtrapolated to the issue of permanent pacemaker implantation in
he context of TAVI. Both the MOST study and the DAVID trial
ncluded only patients with sinus node dysfunction, in whom dual
hamber or right atrial pacing would have been technically suitable,
lternative pacing modes. Conversely, TAVI-related permanent
acemaker implantation is the result of transient or permanent
mpairment of atrioventricular (AV) conduction, which was an
xclusion criterion for participation in MOST and DAVID.
oreover, patients undergoing TAVI substantially differ from
atients included in the MOST and DAVID studies in terms of a
igher cardiac risk profile and comorbidities, rendering any extrap-
lation between these studies inappropriate.
As highlighted in the title of our manuscript, we analyzed the
ffect of pacemaker implantation rather than conduction distur-
ances on all-cause mortality. In view of rates of 1-year mortality
n the range of 24% to 31% after TAVI, it remains of interest
hether permanent pacemaker implantation as one of the most
requent TAVI adverse events has a prognostic impact on this
atient population.
As with any pacemaker population, the group of patients with
permanent pacemaker after TAVI is highly heterogeneous by
ature and consists of patients with various pacemaker indications(high-degree AV block, new-onset left bundle branch block with
first-degree AV block, slow atrial fibrillation), variable rates of
ventricular stimulation during follow-up, spontaneous recovery of
AV conduction no longer requiring a pacemaker, as well as
patients with recovery followed by relapse of severe conduction
abnormality. Therefore, the results of our study do not provide
insights on the clinical relevance of a specific conduction abnor-
mality, but describe the clinical prognosis of the event “TAVI-
related pacemaker implantation” under current practice standards.
These standards include post-procedural rhythm monitoring for
48 h to allow for AV conduction recovery and avoidance of
permanent pacemaker implantation in some patients, but also
includes early pacemaker implants in case of severe conduction
disturbances, as it effectively precludes deleterious effects related to
temporary pacemaker dislocation and bradycardia induced ventric-
ular fibrillation. In fact, a growing body of evidence indicates that
TAVI-induced conduction disturbances do not tend to recover
over time, supporting an early, aggressive strategy of permanent
pacemaker implantation (5).
The negative prognostic impact of left bundle branch block
among patients with cardiovascular disease, including ischemic
heart disease and dilated cardiomyopathy, has been previously
shown, and we read with interest the results of the study by
Houthuizen et al. among patients undergoing TAVI. Comparing
this study with ours, the results do not contradict but rather
complement each other as both studies address the issue of
TAVI-induced AV conduction abnormalities but from a different
angle. In this context, it is important to realize that patients
receiving a permanent pacemaker were specifically excluded from
the study by Houthuizen et al. (4), resulting in a different patient
population.
Pacemaker implantation is life-saving among patients with
high-degree AV conduction abnormalities, and it remains to be
seen whether some patients with TAVI-induced left bundle
branch block included in the study by Houthuizen et al. (4) would
have derived a benefit when implanted with a pacemaker. Given
the reports of both recovery as well as late onset of severe
conduction disturbances after TAVI, it remains a difficult clinical
judgment who should undergo permanent pacemaker implanta-
tion. Future efforts with focus both on how to avoid conduction
abnormalities and to define TAVI-specific criteria and on how to
treat them appropriately once they occur will importantly impact
the further evolution of TAVI.
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Post-Conditioning for
ST-Segment Elevation
Myocardial Infarction
I read with interest the paper by Thuny et al. (1) published in the
June 12, 2012, issue of the Journal. The authors adequately
emonstrated the effectiveness of a post-conditioning strategy in
ecreasing the degree of myocardial edema as assessed by cardiac
agnetic resonance and hypothesized how this can be the result of
ecrease in infarct size.
Post-conditioning is, of course, in early stages of development,
nd clinical implications remain to be established as clearly pointed
ut by the authors; the findings of this randomized trial make
ost-conditioning a very promising strategy for the ongoing
mprovement of outcomes in the management of ST-segment
levation myocardial infarction. As such, I am interested to learn
hether the 26 patients not included in the analysis were evenly
istributed between control/intervention groups, because this in-
ormation can potentially affect the final interpretation of the
esults.
Figure 1 Study Enrollment and Randomization
Distribution of the excluded patients according to the treatment allocation. CMR 
Postcond  post-conditioning; TIMI  Thrombolysis In Myocardial Infarction.As post-conditioning transitions to becoming a clinically useful
management strategy for ST-segment elevation myocardial infarc-
tion, data with regard to the safety of the intervention should be
included in future research. Consequently, and given the potential
role this paper can play in the design of future larger phase 3
clinical trials, I would appreciate if the authors could provide
additional information on this issue.
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Reply
We thank Dr. Posada for his comments with regard to our recently
published report (1). In this study, we analyzed the effect of
post-conditioning on myocardial edema and infarct size. Patients
with previous myocardial infarction in the same territory, a
Thrombolysis In Myocardial Infarction flow grade 1, and evi-
dence of coronary collaterals to the area at risk were excluded, to
limit the influence of confounding factors. In Figure 1, we present
additional information with regard to the distribution of the excluded
patients according to the treatment allocation. Five control versus 7
post-conditioned patients were not included, due to absence or poor
ac magnetic resonance; MI  myocardial infarction;cardi
